Nuclidium raises €84M in Series B funding co-led by Angelini Ventures. The funds will accelerate the clinical development of its theranostic pipeline.
Amount Raised
€84 Million
Round Type
Series B
BaselBiotechnologyHealth CareTherapeuticsInvestors
Description
Nuclidium, a Basel-based clinical-stage radiopharmaceutical company, raised €84M in Series B funding. The round was co-led by Angelini Ventures and others, with participation from various investors. The company intends to use the funds for advancing its Copper-61/Copper-67 theranostic pipeline and expanding production capabilities. Regina Hodits from Angelini Ventures will join the Board of Directors.
Quick answer
Nuclidium raised €84 Million in a Series B round, dated July 10, 2025. Investors: DeepTech, Highlight Capital, Kurma Growth Opportunities Fund, Wellington Partners, Climate Fonds, Bayern Kapital, Eurazeo and Vives Partners. Nuclidium is based in Basel, Basel City, Switzerland.
- How much did Nuclidium raise?
- Nuclidium raised €84 Million in a Series B round on July 10, 2025.
- Who invested in Nuclidium?
- DeepTech, Highlight Capital, Kurma Growth Opportunities Fund, Wellington Partners, Climate Fonds, Bayern Kapital, Eurazeo and Vives Partners are named as investors in this round.
- What does Nuclidium do?
- Nuclidium is a clinical-stage biotechnology company based in Basel, Switzerland, developing innovative copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
- Where is Nuclidium based and how big is it?
- Nuclidium is based in Basel, Basel City, Switzerland. Fundz records about 27 employees.
- Who are the decision-makers at Nuclidium?
- Fundz holds 2 contacts at Nuclidium, including the Head of Clinical Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Nuclidium that raised within 45 days of this round, from Fundz verified event records.
- QurAlis raised $20M on August 21, 2025.
- Calidi Biotherapeutics raised $6.9M (Post-IPO Equity) on August 21, 2025.
- CILA Therapeutics raised an undisclosed amount (Grant) on August 15, 2025.
- Eyestem raised $10M (Series B) on August 11, 2025.
- Tevogen Inc. raised $1M (Funding Round) on August 7, 2025.
- Retension Pharmaceuticals raised $15M (Series B) on August 6, 2025.
Who to call at Nuclidium, and when
A new round usually means Nuclidium is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nuclidium raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuclidium, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuclidium. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuclidium raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNuclidium raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.